SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit's post-earnings selloff is driven by strong quarterly results being overshadowed by a weak full-year guidance, with community focus on the switch to include stock-based compensation and ongoing fears that AI threatens TurboTax and DIY tax prep. Bulls argue the drop is overdone, while bears point to slowing growth and competitive pressure.

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS is trending after a brutal post-earnings selloff triggered by weaker-than-expected results, guided-down full-year outlook, and ongoing drag from the Foot Locker acquisition. Community chatter is sharply split between dip buyers calling it a massive overreaction and shorts expect further downside, with many focusing on the Foot Locker deal as the root problem.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Retail traders are piling into CRML as it leads a strong rare-earth/critical minerals sector move, with the community spotlighting heavy volume, scarce shares, the revised European Lithium merger terms, and a building short-squeeze narrative.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Community buzz centers on founder Patrick Soon-Shiong teasing a trial combining targeted radiation with an IL-15/Anktiva immune approach, fueling speculation about the SHINE Lu-177 supply connection and a broader BioShield push. Retail traders are also weighing the heavy short interest, catalysts like label expansions and pipeline updates, and the recent move back toward $8 as a key battleground.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

ZM is in focus after its quarterly earnings and guidance landed with mixed sentiment, as a stronger print was outweighed by softer near-term guidance and bearish options flow. The community sees the company's Anthropic investment and AI optionality as possible offsets that could eventually re-risk the story, but traders are debating whether the move is a dip buy or a technical breakdown.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as investors gear up for earnings, debating whether a strong report will finally break the pattern of selling the news after a seven-day losing streak. The buzz is split between bulls calling the valuation discount illogical and concerns raised by OpenAI's custom chip benchmarks.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Investors are rallying around NUVB after the FDA granted Fast Track designation to its glioma drug safusidenib, with fresh analyst initiations from Cantor Fitzgerald and JPMorgan amplifying the bullish narrative. Community discussion focuses on the best-in-class potential of IBTROZI and safusidenib, along with growing speculation about a future buyout in a hot oncology M&A environment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing heavy attention as the oil market gets slammed between fresh Strait of Hormuz deal/reopening headlines and growing accusations that the administration is deliberately jawboning crude prices lower. Traders are split between calling the drop a manipulated fake-out and positioning for a severe supply shortfall, with the community also citing continued tanker missile incidents and multiweek inventories as proof the geopolitical risk premium remains unresolved.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

HELP is trending as retail traders rally around the psychedelic sector, energized by the new CEO's track record and the fully enrolled Phase 3 trial on track for a Q4 readout. The conversation centers on buyout speculation, dilution fears, and the stock's deep-value positioning relative to higher-valued peers.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

ONON is trending after a sharp selloff tied to disappointing guidance and broader weakness across athletic-apparel retailers, with peers like Nike and Dick's Sporting Goods also under pressure. The community is split between bulls highlighting strong margins, DTC growth, and insider buying, and bears pointing to valuation concerns and softer consumer demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innoviva Specialty Therapeutics Antimicrobial Therapies, XACDURO, ZEVTERA and NUZOLVENCE Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the companys infectious disease therapies, XACDURO (sulbactam/durlobactam for injection), ZEVTERA (ceftobiprole medocaril sodium for injection), and NUZOLVENCE (zoliflodacin) are...

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) delivered earnings and revenue surprises of +5.36% and +5.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets...

Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of +50.00% and +1.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?

Bayer (BAYRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform...

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Nortiva Bio, Inc. (Nortiva) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX drug delivery platform. Nortivas LYNX platform can transform daily pills into long-acting oral therapies with single...

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddys for XACDURO in Select International Markets

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddys Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO...

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Innoviva Inc

Neutral Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Feed

News

Sentiment

Earnings

Fundamentals

Info

INVA Innoviva Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest INVA News